A Phase 1/2 interventional study of Aflibercept and Pemetrexed in Advanced Carcinoma and Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-10.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 1/2, and was the 1st registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 5
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 86 across the 18 interventional studies, 755 across the 2 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
3 of the studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05785767Phase 3Regeneron PharmaceuticalsA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | 2027-09-28 |
| NCT06269133Regeneron PharmaceuticalsEvaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants | 2027-03-31 |
| NCT04077099Regeneron PharmaceuticalsA Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
The study was conducted in two phases. In phase 1, patients with advanced cancer received different doses of aflibercept in combination with approved doses of pemetrexed and cisplatin. The objective of phase 1 was to determine the safest dose of the combined study medications. This dose was administered to patients with previously untreated NSCLC in phase 2. The phase 2 portion of the study determined if the combination is effective in treating NSCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following up to 6 months (24 weeks) prior to the initial administration of aflibercept:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin
Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m\^2) and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin
Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin
Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin
Administered in combination with the other two interventions via intravenous infusion.
Administered in combination with the other two interventions via intravenous infusion.
Also known as: Alimta
Administered in combination with the other two interventions via intravenous infusion.
Also known as: Platinol
Phase 1: Recommended Dose of Aflibercept for Phase 2
Recommended Dose was defined as the highest combination dose at which fewer than 33 percent (%) of participants experienced dose limiting toxicity during the first cycle of therapy.
Time frame: Phase 1: Baseline up to 315 Days
Phase 2: Objective Response Rate
Objective response rate was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking the Baseline sum LD as reference.
Time frame: Phase 2: Baseline (Day 421) up to end of study (Day 972)
Phase 2: Progression-free Survival (PFS)
PFS was defined as the time in days from the date of first study drug administration to the date of first documentation of tumor progression or death from any cause, whichever occurs first, as assessed by the modified RECIST. Median time of PFS was estimated using Kaplan-Meier method.
Time frame: Phase 2: Baseline (Day 421) up to end of study (Day 972)
Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (for example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) was defined as an adverse event with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious AEs.
Time frame: Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
Time frame: Phase 1 and 2: Pre-dose up to Day 22 post-dose
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
Time frame: Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Phase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Aflibercept and Pemetrexed
Cmax is the maximum observed plasma concentration obtained directly from the concentration versus time curve.
Time frame: Phase 1 and 2: Aflibercept: Pre-dose up to Day 22 post-dose; Pemetrexed: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Phase 1 and 2: Total Body Clearance of Aflibercept
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: Phase 1 and 2: Pre-dose up to Day 22 post-dose
Phase 1 and 2: Total Body Clearance of Pemetrexed
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept
Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.
Time frame: Phase 1 and 2: Pre-dose up to Day 22 post-dose
Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed
Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.
Time frame: Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept
Serum samples were analyzed by a validated electrochemiluminescence immunoassay to detect the presence of ADA.
Time frame: Phase 1: Baseline up to 315 Days; Phase 2: Baseline (Day 421) up to Day 739
Phase 1 and 2: Number of Participants With All Grade Glucose Abnormalities
Time frame: Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days
Phase 1 and 2: Number of Participants With All Grade Hematology Abnormalities
Time frame: Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days
The study consisted of 2 phases: phase 1 and phase 2. A total of 18 participants were enrolled in phase 1 of the study and 42 participants were enrolled in phase 2 of the study. Participants enrolled in phase 1 were not eligible for enrollment in phase 2.
| Milestone | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Started | 4 | 7 | 7 | 0 |
| Completed | 1 | 4 | 4 | 0 |
| Not completed | 3 | 3 | 3 | 0 |
| Withdrew: Death | 0 | 0 | 2 | 0 |
| Withdrew: Other un-specified | 3 | 3 | 1 | 0 |
| Milestone | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 42 |
| Completed | 0 | 0 | 0 | 7 |
| Not completed | 0 | 0 | 0 | 35 |
| Withdrew: Death | 0 | 0 | 0 | 7 |
| Withdrew: Physician decision | 0 | 0 | 0 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 |
| Withdrew: Other unspecified | 0 | 0 | 0 | 13 |
Recommended Dose was defined as the highest combination dose at which fewer than 33 percent (%) of participants experienced dose limiting toxicity during the first cycle of therapy.
| mg/kg | Phase 1: All Participants |
|---|---|
| Phase 1: Recommended Dose of Aflibercept for Phase 2 | 6 |
Objective response rate was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking the Baseline sum LD as reference.
| Percentage of Participants | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|
| Phase 2: Objective Response Rate | 23.8 |
PFS was defined as the time in days from the date of first study drug administration to the date of first documentation of tumor progression or death from any cause, whichever occurs first, as assessed by the modified RECIST. Median time of PFS was estimated using Kaplan-Meier method.
| Days | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|
| Phase 2: Progression-free Survival (PFS) | 149 (130 to 212) |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (for example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) was defined as an adverse event with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious AEs.
| Participants | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 | 7 | 7 | 42 |
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
| Day*milligrams per liter (mg/L) | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept | 201 ± 96.5 | 330 ± 251 | 442 ± 152 | 402 ± 100 |
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
| Hour*milligrams per liter (mg/L) | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed | 151 ± 30.0 | 151 ± 32.5 | 162 ± 12.6 | 148 ± 24.3 |
Cmax is the maximum observed plasma concentration obtained directly from the concentration versus time curve.
| mg/L | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Aflibercept | 53.6 ± 7.14 | 68.6 ± 18.7 | 148 ± 108 | 104 ± 26.2 |
| Pemetrexed | 124 ± 12.6 | 112 ± 34.7 | 113 ± 24.6 | 76.8 ± 40.5 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| Liter/Day/kg | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Total Body Clearance of Aflibercept | 0.011 ± 0.004 | 0.016 ± 0.007 | 0.016 ± 0.009 | 0.016 ± 0.004 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| Liter/hour/m^2 | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Total Body Clearance of Pemetrexed | 3.40 ± 0.59 | 3.47 ± 0.84 | 3.10 ± 0.22 | 3.49 ± 0.76 |
Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.
| Days | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept | 3.16 ± 0.570 | 5.53 ± 5.43 | 3.72 ± 1.04 | 4.62 ± 1.46 |
Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.
| Hours | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed | 1.47 ± 0.39 | 1.63 ± 0.22 | 1.73 ± 0.37 | 1.48 ± 0.34 |
Serum samples were analyzed by a validated electrochemiluminescence immunoassay to detect the presence of ADA.
| Participants | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept | 0 | 0 | 1 | 2 |
| Participants | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Hyperglycemia (Non-Fasting) | 4 | 6 | 7 | 37 |
| Hyperglycemia (Fasting) | 1 | 3 | 6 | 6 |
| Hypoglycemia (Non-Fasting) | 0 | 0 | 0 | 5 |
| Hypoglycemia (Fasting) | 0 | 0 | 0 | 0 |
| Participants | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| Absolute Neutrophil Count (ANC) | 2 | 4 | 7 | 13 |
| Hemoglobin | 3 | 7 | 6 | 16 |
| Platelet Count | 2 | 4 | 2 | 8 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 751 Days for Phase 1 and 972 Days for Phase 2 regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | 1/7 (14.3%) | 5/7 (71.4%) | 7/7 (100%) |
| Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | 5/42 (11.9%) | 16/42 (38.1%) | 41/42 (97.6%) |
| Event | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/4 | 2/7 | 0/7 | 1/42 |
| CHOLECYSTITISHepatobiliary disorders | 1/4 | 0/7 | 0/7 | 0/42 |
| CHOLANGITISHepatobiliary disorders | 0/4 | 0/7 | 1/7 | 0/42 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 0/4 | 1/7 | 0/7 | 0/42 |
| FATIGUEGeneral disorders | 0/4 | 1/7 | 0/7 | 0/42 |
| DISEASE PROGRESSIONGeneral disorders | 0/4 | 0/7 | 1/7 | 3/42 |
| CHEST PAINGeneral disorders | 0/4 | 0/7 | 1/7 | 0/42 |
| HYPOTENSIONVascular disorders | 0/4 | 1/7 | 1/7 | 0/42 |
| GINGIVAL INFECTIONInfections and infestations | 0/4 | 1/7 | 0/7 | 0/42 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/4 | 1/7 | 0/7 | 0/42 |
| Event | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin |
|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 4/4 | 5/7 | 6/7 | 28/42 |
| VOMITINGGastrointestinal disorders | 4/4 | 4/7 | 4/7 | 10/42 |
| FATIGUEGeneral disorders | 4/4 | 6/7 | 6/7 | 28/42 |
| FEELING ABNORMALGeneral disorders | 4/4 | 1/7 | 0/7 | 0/42 |
| DYSGEUSIANervous system disorders | 4/4 | 1/7 | 4/7 | 15/42 |
| CONSTIPATIONGastrointestinal disorders | 3/4 | 3/7 | 6/7 | 22/42 |
| HEADACHENervous system disorders | 3/4 | 1/7 | 4/7 | 13/42 |
| ANOREXIAMetabolism and nutrition disorders | 3/4 | 4/7 | 5/7 | 13/42 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 2/4 | 1/7 | 5/7 | 11/42 |
| HYPERTENSIONVascular disorders | 2/4 | 3/7 | 5/7 | 22/42 |
| Age, Categorical(Participants) | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 1 | 5 | 23 | 33 |
| >=65 years | 0 | 6 | 2 | 19 | 27 |
| Sex: Female, Male(Participants) | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 2 | 19 | 28 |
| Male | 1 | 3 | 5 | 23 | 32 |
| Race (NIH/OMB)(Participants) | Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin | Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 2 | 2 |
| White | 3 | 7 | 7 | 36 | 53 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
Ran from Nov 2008 to primary completion in Jun 2011, 31 months.
Results were first posted in Dec 2020, 9 years 5 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept
Carcinoma, Non-Small-Cell Lung →